The data suggests disease deterioration was halved in the six Amyotrophic Lateral Sclerosis (ALS) patients treated with IPL344 over eight months.
List view / Grid view
amyotrophic lateral sclerosis (ALS)
Filter the results
Tofersen reduced expression of the SOD1 gene known to cause amyotrophic lateral sclerosis (ALS) and slowed clinical decline in the Phase I/II trial.
The FDA has granted early-action approval to Exservan for the treatment of ALS, which can be administered safely and easily without water.
The FDA has handed a CRL to Biohaven for its ALS treatment awaiting approval due to concerns regarding the medication’s API.